We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 14, 2021

Effects of Canagliflozin on MACE by Baseline eGFR

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Effects of canagliflozin on major adverse cardiovascular events (MACE) by baseline estimated glomerular filtration rate: pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial
Diabetes Obes Metab 2021 Aug 31;[EPub Ahead of Print], MR Weir, J Gogate, CV Damaraju, R Correa-Rotter, KW Mahaffey

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading